Stock PBYI PUMA BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Puma Biotechnology, Inc.

Equities

PBYI

US74587V1070

Real-time Estimate Cboe BZX
Other stock markets
 12:34:32 2024-04-19 pm EDT 		5-day change 1st Jan Change
4.935 USD -1.10% Intraday chart for Puma Biotechnology, Inc. -5.88% +14.55%
Mar. 20 Puma Biotechnology Plans to Start Breast Cancer Combination Study in Second Half; Shares Rise MT
Mar. 20 Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer CI

Evolution of the average Target Price on Puma Biotechnology, Inc.

Price target over the last 5 years

History of analyst recommendation changes

53f55e02be1d80.jeyRqx5u_g4_RAO7qK0LSc6GRRuPj2L8V7UB9LUw_Ok.-o705CcNp15dB1Tkn8g8E6DREF6ivzqfM_NRkf1Wi4W8ldPJdAioR14TOw~ab0f1d5ef31718b6271098830634f8f6

Analyst Recommendations on Puma Biotechnology, Inc.

HC Wainwright Lowers Price Target on Puma Biotechnology Inc to $8 From $12, Reiterates Buy Rating MT
PUMA BIOTECHNOLOGY : Citigroup Upgrades Puma Biotechnology to Buy From Neutral, Price Target at $11 MT
PUMA BIOTECHNOLOGY : RBC Cuts PT on Puma Biotechnology to $6 From $13, Citing Nerlynx 2021 Sales Estimates; Sector Perform-Speculative Risk Rating Kept MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
4.99 USD
Average target price
4.333 USD
Spread / Average Target
-13.16%
High Price Target
7 USD
Spread / Highest target
+40.28%
Low Price Target
2 USD
Spread / Lowest Target
-59.92%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Puma Biotechnology, Inc.

HC Wainwright
Citigroup
RBC Capital Markets

Ratings for Puma Biotechnology, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. PBYI Stock
  4. Consensus Puma Biotechnology, Inc.